Predictors of Intensive Care Admission Among Adult Patients with Sickle Cell Disease in Eastern Province of Saudi Arabia

Predictors of Intensive Care Admission Among Adult Patients with Sickle Cell Disease in Eastern Province of Saudi Arabia

Mortadah Alsalman,1 Zaenb Alsalman,2 Hussain Abduljaleel Alkhalifa,3 Aman N Alfaraj,3 Ali Alkhalifah,4 Qasem Almulihi5 1Department of Medicine, College of Medicine, King Faisal University, Alahsa, Saudi Arabia; 2Department of Family and Community Medicine, College of Medicine, King Faisal University...

Full description

Bibliographic Details
Main Authors:	Alsalman M, Alsalman Z, Alkhalifa HA, Alfaraj AN, Alkhalifah A, Almulihi Q
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-12-01
Series:	Journal of Blood Medicine
Subjects:	sickle cell disease intensive care unit hydroxyurea
Online Access:	https://www.dovepress.com/predictors-of-intensive-care-admission-among-adult-patients-with-sickl-peer-reviewed-fulltext-article-JBM

Similar Items

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia
by: Mortadah Alsalman, et al.
Published: (2021-12-01)

The impact of Hydroxyurea on the rates of Vaso–occlusive crises in patients with sickle cell disease in Saudi Arabia: a single–center study
by: Sahar Abdullah Alkhalifah, et al.
Published: (2022-11-01)

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
by: Gohal GA, et al.
Published: (2022-11-01)

Minimal doses of hydroxyurea for sickle cell disease
by: C.S.P. Lima, et al.
Published: (1997-08-01)

Clinical and laboratory profile of patients with sickle cell anemia
by: Phelipe Gabriel dos Santos Sant'Ana, et al.

Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
by: Khayat André Salim, et al.
Published: (2004-01-01)

Impact of omega-3 fatty acids supplementation in children with sickle cell disease in Saudi Arabia
by: Shahida Khan, et al.
Published: (2022-06-01)

The use of hydroxycarbamide in children with sickle cell anemia
by: Hafsat Rufai Ahmad, et al.
Published: (2018-01-01)

Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan
by: MIREILLE YAYO- AYE, et al.
Published: (2024-02-01)

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
by: Fernanda Kelle de Souza Santos, et al.
Published: (2011-01-01)

Consensus of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) and the Brazilian Ministry of Health - General management of blood and blood products on the tests necessary for the release of exceptional medicines for sickle cell disease
by: Clarisse Lobo, et al.
Published: (2024-01-01)

Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study
by: Anoosha Habibi, et al.
Published: (2023-02-01)

Health-related quality of life of adolescents with sickle cell disease on hydroxyurea: A case-control study
by: Hayfaa Mohammed Mones, et al.
Published: (2022-01-01)

Hydroxyurea granules for the management of sickle cell disease in children
by: Grace Lovia Allotey-Babington, et al.
Published: (2022-07-01)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
by: Lidiane de Souza Torres, et al.
Published: (2012-01-01)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
by: Lidiane de Souza Torres, et al.
Published: (2012-01-01)

Sickle Cell Anaemia with Antiglobulin Positive Autoimmune Haemolytic Crisis
by: Saniya Khan, et al.
Published: (2023-09-01)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
by: Paul Lumbala Kabuyi, et al.
Published: (2023-08-01)

Chronic osteo-articular changes in patients with sickle cell disease
by: Taciana Fernandes Araújo Ferreira, et al.
Published: (2021-02-01)

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
by: Emily R. Meier, et al.
Published: (2020-11-01)

Moderate dose of hydroxyurea in children with sickle cell disease and stroke. Preliminary results
by: Sergio Machín-García, et al.

Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
by: Fabia Neves, et al.
Published: (2012-01-01)

Optical laser trapping for studying the deformability of sickle red blood cells in response to hydroxyurea
by: Anmar A Hussein, et al.
Published: (2018-01-01)

Hemoglobin F modulation in sickle cell disease: Experience in a single center in Iraqi Kurdistan
by: Adil A Eissa, et al.
Published: (2016-01-01)

Depression among sickle cell anemia patients in the Eastern Province of Saudi Arabia
by: Mohsen Ali Alhomoud, et al.
Published: (2018-01-01)

Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease
by: Thamal Darshana, et al.
Published: (2021-03-01)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
by: Luiz Bernardino Lima da Silva, et al.
Published: (2012-01-01)

Current challenges in the management of patients with sickle cell disease – A report of the Italian experience
by: Giovanna Russo, et al.
Published: (2019-05-01)

Alloimmunization in children with sickle cell disease: A tertiary care experience
by: Sujata Sharma, et al.
Published: (2023-06-01)

Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea
by: Dhiraj Kumar Yadav, et al.
Published: (2020-07-01)

Characterization of Hematopoiesis in Sickle Cell Disease by Prospective Isolation of Stem and Progenitor Cells
by: Seda S. Tolu, et al.
Published: (2020-09-01)

Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents
by: Paavani S. Reddy, et al.
Published: (2022-12-01)

Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review
by: Pagona Flevari, et al.
Published: (2022-12-01)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
by: Joelma Santana dos Santos Neres, et al.
Published: (2023-06-01)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
by: Trisha E. Wong, et al.
Published: (2021-09-01)

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis
by: Naveen Khargekar, et al.
Published: (2024-02-01)

Clinical and laboratory characteristics of children with sickle cell disease on hydroxyurea treated with artemether-lumefantrine for acute uncomplicated malaria
by: Catherine Segbefia, et al.
Published: (2023-11-01)

Socioeconomic and demographic characteristics of sickle cell disease patients from a low-income region of northeastern Brazil
by: Thales Allyrio Araújo de Medeiros Fernandes, et al.
Published: (2015-06-01)

Sickle Cell Disease Knowledge and Reproductive Decisions: A Saudi Cross-Sectional Study
by: Alsalman M, et al.
Published: (2023-03-01)

Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
by: Khuthala Mnika, et al.
Published: (2019-05-01)